No-Exam Term Life Insurance with Psoriasis: Skin-Only vs Psoriatic Arthritis
Written by: Jeff Schmidt | Licensed Insurance Broker | CarePro Insurance Content reviewed for accuracy. Not legal, tax, or financial advice.
Underwriters usually separate mild, skin-only psoriasis from psoriatic arthritis or severe disease that requires systemic medications. The details drive the rate class.
-
Instant online pricing
-
No phone calls required
-
No pressure from agents
Psoriasis Isn't One-Size-Fits-All
Skin-only vs joint involvement (psoriatic arthritis)
Medication type and treatment intensity
Stability, flare frequency, and any functional limitations
Psoriasis covers a broad clinical spectrum, from limited plaques affecting a small body surface area to severe widespread disease with significant systemic inflammation, and life insurance underwriting reflects that entire spectrum rather than treating every psoriasis diagnosis the same way. The PASI (Psoriasis Area and Severity Index) is the clinical classification tool used to categorize disease as mild, moderate, or severe, and while underwriters do not always have the PASI score itself in front of them, the treatment history in the medical record functions as a direct proxy for where a given case falls on that scale. A mild PASI designation treated topically has a fundamentally different underwriting profile than a high PASI designation requiring systemic immune suppression, and carriers have built their rate tables to reflect those distinctions rather than treating a topical steroid user the same as a biologic therapy recipient.
Medication history is one of the clearest and most reliable signals underwriters use to gauge psoriasis severity, because treatment intensity directly follows clinical severity guidelines. Topical-only treatment - corticosteroids of varying potencies, vitamin D analogues such as calcipotriene, topical retinoids, or topical calcineurin inhibitors - signals mild to moderate disease with localized involvement, and underwriting review for these cases tends to be routine and uncomplicated. When treatment has escalated to conventional systemic DMARDs such as methotrexate, cyclosporine, or acitretin, underwriters treat that as a clear indicator of moderate to severe disease requiring systemic immune modulation, and the review becomes more detailed. Biologic therapies - TNF inhibitors such as adalimumab or etanercept, IL-17 inhibitors such as secukinumab or ixekizumab, and IL-23 inhibitors such as guselkumab or risankizumab - signal severe disease by definition and trigger the most detailed underwriting inquiry, including questions about dosing intervals, infusion history, any infections or hospitalizations occurring during biologic therapy, and whether the current biologic is the original one prescribed or a switch from an earlier agent.
Psoriatic arthritis is underwritten on a separate track from skin-only psoriasis because joint involvement introduces chronic systemic inflammation, potential functional limitation, and a treatment burden that skin-limited disease rarely requires. Within psoriatic arthritis, the specific pattern of joint involvement matters to underwriters. Purely peripheral joint disease - affecting fingers, toes, wrists, or knees in an asymmetric pattern - is evaluated differently than axial disease involving the sacroiliac joints or spine, particularly when imaging has confirmed sacroiliac inflammation or spinal changes consistent with spondyloarthropathy. HLA-B27 positive cases with sacroiliac involvement signal a more aggressive disease course that shares features with ankylosing spondylitis and are typically reviewed with greater scrutiny. Carriers may ask specifically whether imaging has documented axial changes, because that documentation directly determines whether the case is classified as peripheral-only or as an axial spondyloarthropathy for underwriting purposes.
Stability and treatment escalation history over time are the two dimensions underwriters assess most consistently when evaluating any psoriasis or psoriatic arthritis case. A case where the same topical regimen has been used unchanged for several years with stable, limited disease is viewed as a predictable and manageable condition. A case where treatment has been stepped up progressively - from topicals to DMARDs to one biologic and then to a second biologic after the first lost efficacy - suggests a condition that has been difficult to control and is still finding its treatment equilibrium. Recent biologic switches are particularly notable because they often indicate secondary treatment failure, which raises questions about disease trajectory that a stable long-term treatment plan does not. The frequency of dermatology and rheumatology follow-up appointments also provides a signal about how actively the condition is being managed.
When you compare quotes, be precise about the specific elements of your history that have the greatest underwriting impact: whether your diagnosis is skin-only psoriasis or confirmed psoriatic arthritis, the exact medications you currently take, the date of your last medication change or dose adjustment, and whether your symptoms have been stable at their current treatment level without recent flares or escalation. Conflating the two diagnoses or understating treatment intensity produces a quote that will be materially reconsidered once underwriting reviews records. Providing accurate input from the start - even if it produces a less favorable initial estimate - saves the time and disappointment that comes from a well-priced quote that cannot survive medical record review.
For the full instant/no-exam term life guide and underwriting basics, see: https://www.careproinsurance.com/instant-term-life-insurance
None of this material should be treated as legal, medical, or tax advice. Quotes are estimates and final decisions depend on underwriting and carrier guidelines.
Frequently Asked Questions
Can I get no-exam term life insurance with psoriasis?
Often, yes - especially with mild, skin-only psoriasis that's stable. More severe cases or psoriatic arthritis may involve additional underwriting review.
Does psoriatic arthritis affect underwriting differently?
It can. Joint involvement and functional limitation may lead to stricter underwriting than skin-only psoriasis, depending on severity and stability.
Do biologics or systemic medications change life insurance pricing?
They can. Carriers may view systemic treatment as a signal of more significant disease. The outcome depends on stability, dose history, and the overall health profile.
Will I need a medical exam because of psoriasis?
Not always. Some cases qualify for accelerated/no-exam paths, but additional requirements can be triggered by severity, age, higher coverage amounts, or related conditions.
What should I have ready before applying?
Helpful details include diagnosis type (psoriasis vs psoriatic arthritis), current medications, recent flare history, and whether symptoms limit daily activity.
Can mild, topical-only psoriasis qualify for a preferred or preferred-plus rate class?
It is possible at carriers whose guidelines do not rate mild stable psoriasis, and where other health and lifestyle factors support a preferred tier. Mild psoriasis affecting a small body surface area, treated only with topical agents, with no joint involvement and a stable history for multiple years is not automatically a barrier to preferred pricing. However, preferred and preferred-plus tiers also require meeting specific thresholds on build, blood pressure, cholesterol, and family history - psoriasis is one factor among several in that determination.
Does psoriasis carry cardiovascular risk implications that underwriters factor in?
Underwriters are aware that moderate to severe psoriasis is associated with elevated cardiovascular risk in clinical literature, driven by chronic systemic inflammation. For cases involving biologics or systemic DMARDs, some carriers factor this context into the broader review by also examining blood pressure, cholesterol, and metabolic markers more closely than they might for an unrelated applicant of the same age. This does not automatically produce a rating, but it explains why severe psoriasis cases sometimes involve more cardiovascular-related questions than the skin condition alone would seem to require.
What if I have psoriasis but have never been formally evaluated by a dermatologist?
A psoriasis history managed entirely by a primary care physician without dermatology consultation is not automatically a disqualifier, but it may prompt questions. Underwriters want to confirm the diagnosis was properly evaluated and that the treatment approach reflects the actual clinical severity. If there has been no specialist evaluation for a condition that appears moderate or severe based on treatment history, some carriers may request records to assess the clinical picture before completing their decision.
Related Pages and Helpful Resources
Read the Full Guide Here:
Get Covered With The Right Plan
Psoriasis can be straightforward when it's skin-only, but joint involvement and systemic medications can change underwriting. Explain the split clearly.
Check term life quotes